212 related articles for article (PubMed ID: 33011861)
1. Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses.
Ozaki Y; Imamaki H; Ikeda A; Oura M; Nakagawa S; Funakoshi T; Kataoka S; Nishikawa Y; Horimatsu T; Yonezawa A; Matsubara T; Yanagita M; Muto M; Watanabe N
Cancer Chemother Pharmacol; 2020 Nov; 86(5):693-699. PubMed ID: 33011861
[TBL] [Abstract][Full Text] [Related]
2. Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia.
Nishikawa Y; Funakoshi T; Horimatsu T; Miyamoto S; Matsubara T; Yanagita M; Nakagawa S; Yonezawa A; Matsubara K; Muto M
Cancer Chemother Pharmacol; 2017 Mar; 79(3):629-633. PubMed ID: 28204913
[TBL] [Abstract][Full Text] [Related]
3. Removal rate of 5-fluorouracil and its metabolites in patients on hemodialysis: a report of two cases of colorectal cancer patients with end-stage renal failure.
Imamaki H; Oura M; Oguro F; Nishikawa Y; Nakagawa S; Funakoshi T; Kataoka S; Horimatsu T; Yonezawa A; Matsubara T; Watanabe N; Muto M; Yanagita M; Ozaki Y
Cancer Chemother Pharmacol; 2024 Feb; 93(2):161-167. PubMed ID: 37608127
[TBL] [Abstract][Full Text] [Related]
4. Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil.
Thiberville L; Compagnon P; Moore N; Bastian G; Richard MO; Hellot MF; Vincent C; Kannass MM; Dominique S; Thuillez C
Cancer Chemother Pharmacol; 1994; 35(1):64-70. PubMed ID: 7987979
[TBL] [Abstract][Full Text] [Related]
5. [A case of 5-fluorouracil-induced hyperammmonia after chemotherapy for metastatic colon cancer].
Nakamura M; Kobashikawa K; Tamura J; Takaki R; Ohshiro M; Matayoshi R; Hirata T; Kinjyo F; Fujita J
Nihon Shokakibyo Gakkai Zasshi; 2009 Dec; 106(12):1744-50. PubMed ID: 19966516
[TBL] [Abstract][Full Text] [Related]
6. 5-Fluorouracil, epirubicin, and mitomycin C versus 5-fluorouracil, epirubicin, mitomycin C, and leucovorin in advanced gastric carcinoma. A randomized trial.
Tsavaris NB; Tentas K; Kosmidis P; Mylonakis N; Sakelaropoulos N; Kosmas C; Lisaios B; Soumilas A; Mandrekois D; Tsetis A; Klonaris C
Am J Clin Oncol; 1996 Oct; 19(5):517-21. PubMed ID: 8823483
[TBL] [Abstract][Full Text] [Related]
7. Retrospective comparative analysis of 5FU + low-dose folinic acid vs. 5FU + high-dose folinic acid in the treatment of metastatic colorectal cancer. The Ottawa experience.
Maroun JA; Cripps C; Goel R; Dahrouge S; Boisvert D
Am J Clin Oncol; 1997 Aug; 20(4):387-92. PubMed ID: 9256896
[TBL] [Abstract][Full Text] [Related]
8. Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial.
Ducreux M; Bouche O; Pignon JP; Mousseau M; Raoul JL; Cassan P; Leduc B; Berger C; Dunant A; Fournet J; Bedenne L;
Oncology; 2006; 70(3):222-30. PubMed ID: 16816536
[TBL] [Abstract][Full Text] [Related]
9. [Four cases of 5-fluorouracil-related hyperammonemia in patients with large intestinal cancer and multiple liver metastases, including a case of hyperammonemia treated using hemodialysis].
Iida T; Wagatsuma K; Tani M; Sasaki H; Naganawa Y; Isshiki H; Murakami K; Satoh S; Shimizu H; Kaneto H
Nihon Shokakibyo Gakkai Zasshi; 2015 Feb; 112(2):287-96. PubMed ID: 25748155
[TBL] [Abstract][Full Text] [Related]
10. Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil.
Cascinu S; Aschele C; Barni S; Debernardis D; Baldo C; Tunesi G; Catalano V; Staccioli MP; Brenna A; Muretto P; Catalano G
Clin Cancer Res; 1999 Aug; 5(8):1996-9. PubMed ID: 10473077
[TBL] [Abstract][Full Text] [Related]
11. [Levofolinate and fluorouracil combination therapy].
Takeuchi S; Murakami M
Nihon Yakurigaku Zasshi; 2001 Sep; 118(3):211-8. PubMed ID: 11577462
[TBL] [Abstract][Full Text] [Related]
12. Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106).
Shirao K; Boku N; Yamada Y; Yamaguchi K; Doi T; Goto M; Nasu J; Denda T; Hamamoto Y; Takashima A; Fukuda H; Ohtsu A;
Jpn J Clin Oncol; 2013 Oct; 43(10):972-80. PubMed ID: 24014884
[TBL] [Abstract][Full Text] [Related]
13. [Coma following chemotherapy: is 5FU implicated? Discussion about on case-report].
Heluwaert F; Santre C; Martin C; Hilleret MN; Martin D
Gastroenterol Clin Biol; 2006 Feb; 30(2):325-6. PubMed ID: 16565673
[TBL] [Abstract][Full Text] [Related]
14. 5-Fluorouracil plus interferon alpha-2a compared to 5-fluorouracil alone in the treatment of advanced colon carcinoma: a multicentric randomized study.
Palmeri S; Meli M; Danova M; Bernardo G; Leonardi V; Dastoli G; Rausa L; Russo A; Filippelli G; Palmieri G; Russo A; Della Vittoria Scarpati M; Lo Russo V; Di Lauro L; Colucci G; Bruni G; Piazzi M; Gebbia N; Spada S
J Cancer Res Clin Oncol; 1998; 124(3-4):191-8. PubMed ID: 9619746
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
Tominaga K; Higuchi K; Okazaki H; Suto R; Hamaguchi M; Tanigawa T; Sasaki E; Shiba M; Watanabe T; Fujiwara Y; Oshitani N; Matsumoto T; Arakawa T
Oncology; 2004; 66(5):358-64. PubMed ID: 15331922
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.
Saltz LB; Kanowitz J; Kemeny NE; Schaaf L; Spriggs D; Staton BA; Berkery R; Steger C; Eng M; Dietz A; Locker P; Kelsen DP
J Clin Oncol; 1996 Nov; 14(11):2959-67. PubMed ID: 8918493
[TBL] [Abstract][Full Text] [Related]
17. 5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine.
Muneoka K; Shirai Y; Yokoyama N; Wakai T; Hatakeyama K
Int J Clin Oncol; 2005 Dec; 10(6):441-3. PubMed ID: 16369751
[TBL] [Abstract][Full Text] [Related]
18. Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients.
Arshad U; Ploylearmsaeng SA; Karlsson MO; Doroshyenko O; Langer D; Schömig E; Kunze S; Güner SA; Skripnichenko R; Ullah S; Jaehde U; Fuhr U; Jetter A; Taubert M
Cancer Chemother Pharmacol; 2020 Apr; 85(4):711-722. PubMed ID: 32152679
[TBL] [Abstract][Full Text] [Related]
19. Phase II evaluation of low-dose continuous 5-fluorouracil and weekly cisplatin in advanced adenocarcinoma of the stomach. A Southwest Oncology Group study.
Williamson SK; Tangen CM; Maddox AM; Spiridonidis CH; Macdonald JS
Am J Clin Oncol; 1995 Dec; 18(6):484-7. PubMed ID: 8526189
[TBL] [Abstract][Full Text] [Related]
20. 5-Fluorouracil-induced hyperammonaemic encephalopathy: A French national survey.
Boilève A; Thomas L; Lillo-Le Louët A; Gaboriau L; Chouchana L; Ducreux M; Malka D; Boige V; Hollebecque A; Hillaire-Buys D; Jozwiak M
Eur J Cancer; 2020 Apr; 129():32-40. PubMed ID: 32120273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
